新型冠状病毒肺炎最新研究进展

郭倩; 黄明月; 龚磊; 吴家兵

doi:10.19837/j.cnki.ahyf.2022.03.015

PDF(837 KB)

安徽预防医学杂志 ›› 2022, Vol. 28 ›› Issue (3) : 234-238. DOI: 10.19837/j.cnki.ahyf.2022.03.015

综述

新型冠状病毒肺炎最新研究进展

郭倩¹, 黄明月¹, 龚磊², 吴家兵^1,2

作者信息 +

The latest research progress of SARS-CoV-2

GUO Qian^*, HUANG Ming-yue, GONG Lei, WU Jia-bing

Author information +

文章历史 +

摘要

目的新型冠状病毒肺炎(简称“COVID-19”)是全球关注的重要公共卫生问题,新冠病毒的变异、疫苗研发、复阳病例、临床救治等一系列问题给疫情防控增加了难度。本文从病原学、流行病学、临床特征、防控措施等方面进行综述,以期为新冠肺炎疫情防控提供科学依据。

Abstract

Objective Novel coronavirus pneumonia (" COVID-19 ") is an important public health issue of global concern.A series of problems such as mutation of novel coronavirus,vaccine research and development,re-positive cases,and clinical treatment have increased the difficulties to the prevention and control of the epidemic.In this review,the etiology,epidemiological characteristics,clinical characteristics,prevention and control measures and other aspects will be reviewed in order to provide scientific basis for epidemic prevention and control of COVID-19.

导出引用

郭倩, 黄明月, 龚磊, 吴家兵. 新型冠状病毒肺炎最新研究进展[J]. 安徽预防医学杂志. 2022, 28(3): 234-238 https://doi.org/10.19837/j.cnki.ahyf.2022.03.015

GUO Qian, HUANG Ming-yue, GONG Lei, WU Jia-bing. The latest research progress of SARS-CoV-2[J]. Anhui Journal of Preventive Medicine. 2022, 28(3): 234-238 https://doi.org/10.19837/j.cnki.ahyf.2022.03.015

中图分类号： R183

参考文献

[1] World Health Organization.Daily cases and deaths by date reported to WHO [DB/OL].(2022-04-26).https://covid19.who.int/info.
[2] Chan JF-W,Kok K-H,Zhu Z,et al.Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan[J].Emerging Microbes & Infections,2020,9(1):221-236.
[3] Lu R,Zhao X,Li J,et al.Genomic characterisation and epidemiology of 2019 novel coronavirus:implications for virus origins and receptor binding[J].The Lancet,2020,395(10224):565-574.
[4] Wan Y,Shang J,Graham R,et al.Receptor Recognition by the Novel Coronavirus from Wuhan:an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus[J].J Virol,2020,94(7):e00127-20.
[5] Wrapp D,Wang NS,Corbett KS,et al.Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation[J].Science,2020,367(6483):1260-1263.
[6] 黄虞远,张思慧,周娟,等.新型冠状病毒在环境中的存活潜力和感染风险[J].疾病监测,2021,36(1):16-22.
[7] 国家卫生健康委.关于印发新型冠状病毒肺炎诊疗方案(试行第八版修订版)的通知[A/OL].(2021-04-15).http://www.nhc.gov.cn/yzygj/s7653p/202104/7de0b3837c8b4606a0594aeb0105232b.shtml.
[8] Yin C.Genotyping coronavirus SARS-CoV-2:methods and implications[J].Genomics,2020,112(5):3588-3596.
[9] Plante JA,Liu Y,Liu J,et al.Spike mutation D614G alters SARS-CoV-2 fitness[J].Nature,2021,592(7852):116-121.
[10] Calistri P,Amato L,Puglia I,et al.Infection sustained by lineage B.1.1.7 of SARS-CoV-2 is characterised by longer persistence and higher viral RNA loads in nasopharyngeal swabs.Int J Infect Dis,2021,105:753-755.
[11] Davies NG,Abbott S,Batnard RC,et al.Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England.Science,2021,372(6538):eabg3055.
[12] Nelson G,Buzko O,Spilman P,et al.Molecular Dynamic Simulation Reveals E484K Mutation Enhances Spike RBD-ACE2 Affinity and the Combination of E484K,K417N and N501Y Mutations (501Y.V2 Variant) Induces Conformational Change Greater than N501Y Mutant Alone,Potentially Resulting in an Escape Mutant[J].bioRxiv,2021 DOI:10.1101/2021.01.13.426558.
[13] Faria NR,Mellan TA,Whittaker C,et al.Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus,Brazil[J].Science,2021,372(6544):815-821.
[14] Kai K.New variants have changed the face of the pandemic.What will the virus do next? [A/OL],(2021-08-19).https://www.science.org/content/article/new-sars-cov-2-variants-have-changed-pandemic-what-will-virus-do-next.
[15] Fisman DN,Tuite AR.Evaluation of the relative virulence of novel SARS-CoV-2 variants:a retrospective cohort study in Ontario,Canada[J].CMAJ,2021,193(42):E1619-E1625.
[16] Planas D,Veyer D,Baidaliuk A,et al.Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization[J].Nature,2021,596(7871):276-280.
[17] Manase E.Covid-19:Hospital admission 50-70% less likely with omicron than delta,but transmission a major concern[J].BMJ,2021,375:n3151.
[18] Nyberg T,Ferguson NM,Nnash SG,et al.Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2omicron (B.1.1.529) and delta (B.1.617.2) variants in England:a cohort study[J].Lancet,2022,399(10332):1303-1312.
[19] Gisaid EpiCoV.Tracking of Variants[A/OL].[2022-04-26].https://www.gisaid.org/hcov19-variants/.
[20] 陈嘉源,施劲松,丘栋安,等.2019新型冠状病毒基因组的生物信息学分析[J].生物信息学,2020,18(2):96-102.
[21] Xiao K,Zhai J,Feng Y,et al.Isolation of SARS-CoV-2-related coronavirus from Malayan pangolins[J].Nature,2020,583(7815):286-289.
[22] Zhao X,Chen D,Szabla R,et al.Broad and Differential Animal Angiotensin-Converting Enzyme 2 Receptor Usage by SARS-CoV-2[J].J Virol,2020,94(18):e00940-20.
[23] 杨孝坤,李昱,赵宏婷,等.新型冠状病毒感染不同阶段的传染性研究进展[J].中华流行病学杂志,2021,42(1):33-38.
[24] Yu P,Zhu J,Zhang Z,et al.A Familial Cluster of Infection Associated With the 2019 Novel Coronavirus Indicating Possible Person-to-Person Transmission During the Incubation Period[J].J Infect Dis,2020,221(11):1757-1761.
[25] 吴俣,刘民.不同新型冠状病毒变异株感染的COVID-19潜伏期研究[J].中国全科医学,2022,25(11):1309-1313,1319.
[26] 高翔,陈伟,郭丽,等.新型冠状病毒肺炎无症状感染者及其对疫情防控的挑战[J].中华流行病学杂志,2020,41(12):1985-1988.
[27] Johansson MA,Quandelacy TM,Kada S,et al.SARS-CoV-2 Transmission From People Without COVID-19 Symptoms[J].JAMA Netw Open,2021,4(1):e2035057.
[28] Lai CC,Shih TP,Ko WC,et al.Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19):The epidemic and the challenges[J].Int J Antimicrob Agents,2020,55(3):105924.
[29] Shen Y,LI C,Dong H,et al.Community Outbreak Investigation of SARS-CoV-2 Transmission Among Bus Ridersin Eastern China[J],JAMA Intern Med,2020,180(12):1665-1671.
[30] Ong Swx,Tan YK,Chia PY,et al.Air,Surface Environmental,and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient[J].JAMA,2020,323(16):1610-1612.
[31] 中华医学会呼吸病学分会.中国成人2019冠状病毒病的诊治与防控指南[J].2021,101(18):1293-1356.
[32] Chen Y,Chen L,Deng Q,et al.The presence of SARS-CoV-2 RNA in the feces of COVID-19 patients[J].J Med Virol,2020,92(7):833-840.
[33] 高学欢,郭倩,吴家兵,等.安徽省2020年47例新型冠状病毒肺炎未成年患者的流行病学及临床特征分析[J].安徽预防医学杂志,2021,27(5):386-389.
[34] Davies NG,Klepac P,Liu Y,et al.Age-dependent effects in the transmission and control of COVID-19 epidemics[J].Nat Med,2020,26(8):1205-1211.
[35] Wu Z,Mcgoogan JM.Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China:Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention[J].JAMA,2020,323(13):1239-1242.
[36] Liu Y,Mao B,Liang S,et al.Association between age and clinical characteristics and outcomes of COVID-19[J].Eur Respir J,2020,55(5):2001112.
[37] Huang C,Wang Y,LI X,et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan,China[J].The Lancet,2020,395(10223):497-506.
[38] 郑丹文,翁衡,刘云涛,等. 广州Delta新冠病毒变异株感染的新型冠状病毒肺炎临床特征的真实世界研究 [J] .中华急诊医学杂志,2021,30(10) :1220-1228.
[39] 吴俣,刘珏,刘民,等 .新型冠状病毒 Omicron 变异株的流行病学特征及防控研究[J].中国全科医学,2022,25(1):14-19.
[40] Mattiuzzi C,Henry BM,Sanchis-Gomar F,et al.SARS-CoV-2 recurrent RNA positivity after recovering from coronavirus disease 2019 (COVID-19):a meta-analysis[J].Acta Biomed,2020,91(3):e2020014.
[41] 冯春森,裴家强,陈燕红,等.新型冠状病毒肺炎复阳患者的临床特点、预后及传染性[J].重庆医学,2021,50(6):945-948.
[42] 施丽泳,蔡艳萍,张祎祥,等.新型冠状病毒肺炎核酸复阳患者与未复阳患者临床特征比较[J].中华结核和呼吸杂志,2020,43(12):1066-1070.
[43] Yao XH,He ZC,Li TY,et al.Pathological evidence for residual SARS-CoV-2 in pulmonary tissues of a ready-for-discharge patient[J].Cell Research,2020,30(6):541-543.
[44] Zou Y,Wang BR,Sun L,et al.The Issue of Recurrently Positive Patients Who Recovered From COVID-19 According to the Current Discharge Criteria:Investigation of Patients from Multiple Medical Institutions in Wuhan,China[J].J Infect Dis,2020,222(11):1784-1788.
[45] 香港特别行政区卫生部署卫生防护中心和医院管理局.2019冠狀病毒病第5波数据[A/OL].(2022-04-26).https://www.covidvaccine.gov.hk/pdf/5th_wave_statistics.pdf.
[46] Yang ZN,Zhao YY,Li L,et al.Evaluation of safety of two inactivated COVID-19 vaccines in a large-scale emergency use[J].Zhonghua Liu Xing Bing Xue Za Zhi,2021,42:1-6.
[47] Amit S,Rrgev-yochay G,AFEK A,et al.Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients[J].Lancet,2021,397(10277):875-877.
[48] Voysey M,Clemens SAC,Madhi SA,et al.Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2:an interim analysis of four randomised controlled trials in Brazil,South Africa,and the UK[J].The Lancet,2021,397(10269):99-111.
[49] Konstantinides S.Thrombotic complications of vaccination against SARS-CoV-2:what pharmacovigilance reports tell us - and what they don't[J].Eur Respir J,2021,58(1):210111.
[50] Borchering RK,Viboud C,Howerton E,et al.Modeling of Future COVID-19 Cases,Hospitalizations,and Deaths,by Vaccination Rates and Nonpharmaceutical Intervention Scenarios - United States,April-September 2021[J].MMWR Morb Mortal Wkly Rep,2021,70(19):719-724.
[51] Moore S,Hill EM,Tildesley MJ,et al.Vaccination and non-pharmaceutical interventions for COVID-19:a mathematical modelling study[J].Lancet Infect Dis,2021,21(6):793-802.
[52] Leung NHL,Chu DKW,Shiu EYC,et al.Respiratory virus shedding in exhaled breath and efficacy of face masks[J].Nat Med,2020,26(5):676-680.
[53] Huang B,Wang J,Cai J,et al.Integrated vaccination and physical distancing interventions to prevent future COVID-19 waves in Chinese cities.[J],Nat Hum Behav,2021,5(6):695-705.
[54] 国务院应对新型冠状病毒肺炎疫情联防联控机制综合组.进口冷链食品预防性全面消毒工作方案[J].中国病毒病杂志,2021,11(1):56.
[55] 国务院应对新型冠状病毒肺炎疫情联防联控机制综合组.关于加强口岸城市新冠肺炎疫情防控工作的通知[A/OL].[2021-11-25].http://www.nhc.gov.cn/jkj/s7916/202112/d82d084324e446a983d2816c1f69ee23.shtml.